Patients with monoclonal gammopathies either benign or malignant may develop inflammatory symptoms such as Schnitzler syndrome. We proposed to name those cases as monoclonal gammopathy of inflammatory significance, or MGIS.
The aim of the study is to search for inflammatory pathway that may be activated in case MGIS and to search if the genetic of tumoral cell could explain those activations.
Patient over 18 years of age with the capacity to give express free and informed consent.
Patient followed in one of the services participating in the study and meeting the 2 following conditions
have myelodysplastic syndrome, or multiple myeloma, or monoclonal gammopathy of undetermined significance, or Schnitzler's syndrome.
have a fever of undetermined etiology associated with one of the following symptoms: rash, arthralgia or arthritis, serositis, abdominal pain.
Patient incapable of giving express free and informed consent.
Subject under guardianship, curatorship or safeguarding of justice.
Subject does not speak French.
Subject incapable of answering questions or expressing himself/herself.
Inpatients and out wil be recruited in tertiary university centre of the Assitance Publique des Hopitaux de Paris.
Cohort
Prospective
Not listed
Whole exome sequencing of tumoral cells
We will perform a genetic study of tumoral cells using whole exome sequencing, We will use high throughput genetic sequencing technics, with help of a Nova seq 6000. We will use patients tumoral cells to do it.
Cytokine profile measurement, with ELISA or quantitative PCR.
Measurment of main inflammatory cytokine using ELISA, PCR and flow-cytometry. This measurement will be done on leukocytes and plasma from patients.
Click on the lead sponsor to view all of their trials.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
INSERM UMR 1163
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
